

LAHIVE
&
COCKFIELD
L L P

COUNSELLORS AT LAW
28 STATE STREET
BOSTON, MASSACHUSETTS 02109-1784
TELEPHONE (617) 227-7400
FAX (617) 742-4214
www.lahive.com

JOHN A. LAHIVE, JR. (1928-1997)
THOMAS V. SMURZYNSKI
GIULIO A. DeCONTI, JR.
ELIZABETH A. HANLEY
AMY BAKER MANDRAGOURAS
ANTHONY A. LAURENTANO
KEVIN J. CANNING
JANE E. REMILLARD
DeANN FORAN SMITH
DEBRA J. MILASINIC, Ph.D.
WILLIAM A. SCOFIELD, JR.
SIBLEY P. REPPERT
DAVID R. BURNS
JOHN S. CURRAN
SEAN D. DETWEILER
MEGAN E. WILLIAMS, Ph.D.
LISA DIROCCO TYNER
HATHAWAY P. RUSSELL
MARIA LACCOTRIPE ZACHARAKIS, Ph.D.

MERIDETH C. ARNOLD
DANIELLE L. HERRITT
EUIHOON LEE **
MANEESH GULATI
CYNTHIA M. SOROS
PETER W. DINI, Ph.D.
MICHAEL J. BASTIAN, Ph.D.
CHRISTOPHER J. MCKENNA
VINCENT P. LOCCISANO

SENIOR COUNSEL
JAMES E. COCKFIELD

OF COUNSEL
JEREMIAH LYNCH
JEANNE M. DIGIORGIO
CYNTHIA L. KANIK, Ph.D.
JOHN D. LANZA

PATENT AGENTS
JONATHAN M. SPARKS, Ph.D.
ANDRINA WILLIAMS ZINK
CRISTIN E. HOWLEY, Ph.D.
JILL ANN MELLO, Ph.D.
CHRISTOPHER E. DRABIK

TECHNICAL SPECIALISTS
CATHERINE M. BISHOP
JACOB G. WEINTRAUB
DEBORAH L. NAGLE, Ph.D.
ANNE JACQUELINE WIZEMAN, Ph.D.
BRIAN C. TRINQUE, Ph.D.
CHRISTOPHER R. COWLES, Ph.D.
JAMES H. VELEMA
W. ELANA WANG

* Admitted in TX only
** Admitted in CT only

August 26, 2004

The PTO did not receive the following
listed item(s) All 'FOR's & 'NPL's

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Re: U.S. Patent Application No.: 10/627307
For: METHODS AND COMPOSITIONS FOR TREATING MACROPHAGE-MEDIATED DISEASES
Inventor: van de Winkel, J.G.J.
Filed: July 25, 2003
Our Ref. No.: MXI-101CPACN


Dear Sir:

I enclose herewith for filing in the above-identified application the following:


1. Information Disclosure Statement;
2. PTO Form SB-08; and
3. A Return Postcard.

No additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450:

26 August 04
Date

Jeanne M. DiGiorgio, Reg. No. 41,710

Respectfully submitted,
LAHIVE & COCKFIELD, LLP


Jeanne M. DiGiorgio
Registration No. 41,710
Attorney for Applicant



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: van de Winkel, J.G.J.

Serial No.: 10/627307

Filed: July 25, 2003

For: METHODS AND COMPOSITIONS FOR
TREATING MACROPHAGE-MEDIATED
DISEASES

Attorney Docket No.: MXI-101CPACN

Group Art Unit: 3763

Examiner: Not Yet Assigned

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on the date set forth below.

26 August 04
Date of Signature and of Mail Deposit

By:


Jeanne M. DiGiorgio
Registration No. 41,710
Attorney for Applicant

INFORMATION DISCLOSURE STATEMENT


Dear Sir:

Applicant and his Attorney are aware of the following patents, publications or other information, which are cited on the attached PTO Form 1449, and in accordance with 37 CFR §1.97 hereby submit these publications for the Examiner's consideration. The present application is a Continuation Application of U.S. Serial No. 09/251570, filed February 17, 1999 (Atty. Docket No. MXI-101CPACN). All references listed on the enclosed PTO Form 1449 have been previously cited by or submitted to the Office in the prior application, and, in accordance with 37 CFR §1.98(d), copies of these references are not enclosed herewith, but will be provided upon request.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicant understands that the Examiner will make an independent evaluation of the cited publications.

Under 37 CFR § 1.97(b)(3), no additional costs are believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fee as required under 37 CFR §1.17(p) to our Deposit Order Account No. 12-0080.

Respectfully submitted,
LAHIVE & COCKFIELD, LLP


Jeanne M. DiGiorgio
Registration No. 41,710
Attorney for Applicant

28 State Street
Boston, MA 02109
(617) 227-7400

Date: 26 August 04

GAD/JER/JMD/alf

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO MXI-101CPACN	SERIAL NO. 10/627307
53 PAGES OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary) AUG 30 2004		APPLICANT	van de Winkel, J.G.J.	
		FILING DATE July 25, 2003	GROUP 3763	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
A1	4,470,925	09/84	Auditore-Hargreaves	260	112 B	
A2	4,676,980	06/87	Segal et al.	424	85	
A3	4,954,617	09/90	Fanger et al.	530	387	
A4	5,635,600	06/97	Fanger et al.	530	387.3	
A5	5,767,106	06/98	Turley et al.	514	54	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
A6	WO 91/00360	01/91	PCT				
A7	WO 91/03493	03/91	PCT				
A8	WO 91/05871	05/91	PCT				
A9	WO 92/05793	04/92	PCT				
A10	WO 94/10332	05/94	PCT				
A11	WO 95/09002	04/95	PCT				

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

A12	Andrews, R. et al. (1986) "The L4F3 Antigen is Expressed by Unipotent and Multipotent Colony-Forming Cells but Not by Their Precursors", <i>Blood</i> , <u>68</u> (5):1030-1035;
A13	Ball, E. et al. (1992) "Initial Trial of Bispecific Antibody-Mediated Immunotherapy of CD15-Bearing Tumors: Cytotoxicity of Human Tumor Cells Using a Bispecific Antibody Comprised of Anti-CD15 (MoAb PM81) and Anti-CD64/Fc γ RI (MoAb 32)" <i>Journal of Hematology</i> <u>1</u> :85-94;
A14	Brennan, M. et al. (1985) "Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G ₁ Fragments" <i>Science</i> <u>229</u> : 81-83;
A15	Cuttitta, F. et al. (1981) "Monoclonal Antibodies that Demonstrate Specificity for Several Types of Human Lung Cancer", <i>PNAS</i> , <u>78</u> (7):4591-4595;
A16	Graziano, R. et al. (1995) "Construction and Characterization of a Humanized Anti-Gamma-Ig Receptor Type I (Fc γ RI) Monoclonal Antibody" <i>The Journal of Immunology</i> , <u>155</u> (10):4996-5002;
A17	Guyre, P. et al. (1989) "Monoclonal Antibodies that Bind to Distinct Epitopes on Fc γ RI are Able to Trigger Receptor Function" <i>The Journal of Immunology</i> <u>143</u> (5):1650-1655;
A18	Guyre, P. et al. (1983) "Recombinant Immune Interferon Increases Immunoglobulin G Fc Receptors on Cultured Human Mononuclear Phagocytes" <i>Journal of Clinical Investigation</i> <u>72</u> :393-397;
A19	Harris, W. et al. (1993) "Therapeutic Antibodies - The Coming of Age" <i>Tibtech</i> <u>11</u> :42-44;

Examiner	Date Considered
----------	-----------------

EXAMINER : Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO MXI-101CPACN	SERIAL NO. 10/627307
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT van de Winkel, J.G.J.	
				FILING DATE July 25, 2003	GROUP 3763

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	B1	WO 95/09917	04/95	PCT			
	B2	WO 96/40789	12/96	PCT			
	B3	WO 97/07218	02/97	PCT			
	B4	WO 98/09647	03/98	PCT			

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

B5	Heijnen, I.A.F.M. and van de Winkel, J.G.J. (1995) "A Human Fc γ RI/CD64 Transgenic Model for In Vivo Analysis of (Bispecific) Antibody Therapeutics" <i>Journal of Hematology</i> 4:351-356;
B6	Hird, V. et al. (1990) "Immunotherapy with Monoclonal Antibodies", <i>Genes and Cancer</i> , Edited by D. Carney and K. Sikora, Chapter 17, pp. 183-189;
B7	Kaminski, N.E. et al. (1986) "Target Ricin by Coupling to an Anti-macrophage Monoclonal Antibody" <i>Journal of Immunopharmacology</i> 8(1):15-37;
B8	Karpovsky, B. et al. (1984) "Production of Target-Specific Effector Cells Using Hetero-Cross-Linked Aggregates Containing Anti-Target Cell and Anti-Fc γ Receptor Antibodies" <i>Journal of Experimental Medicine</i> 160:1686-1701;
B9	Liu, M. et al. (1985) "Heteroantibody Duplexes Target Cells for Lysis by Cytotoxic T Lymphocytes" <i>PNAS</i> 82:8648-8652;
B10	Schlom, J. (1991) "Monoclonal Antibodies: They're More and Less Than You Think", <i>Molecular Foundations of Biology</i> Edited by Williams and Wilkins, Chapter 6, pp. 95-134;
B11	Seaver, S. (1994) "Monoclonal Antibodies in Industry: More Difficult Than Originally Thought" <i>Genetic Engineering</i> 14(14):10 & 21;
B12	Shen, L. et al. (1986) "Heteroantibody-Mediated Cytotoxicity: Antibody to the High Affinity Fc Receptor for IgG Mediates Cytotoxicity by Human Monocytes that is Enhanced by Interferon- γ and is not Blocked by Human IgG", <i>The Journal of Immunology</i> 137 (11):3378-3382;
B13	Valerius, T. et al. (December 1997) "Fc α RI (CD89) as a Novel Trigger Molecule for Bispecific Antibody Therapy" <i>Blood</i> 90(11):4485-4492;
B14	Valerius, T. et al. (1997) "HLA Class II Antibodies Recruit G-CSF Activated Neutrophils for Treatment of B Cell Malignancies" <i>Leukemia and Lymphoma</i> 26:261-269;
B15	van de Winkel, J.G.J. et al. (1987) "Characterization of Two Fc Receptors for Mouse Immunoglobulins on Human Monocytes and Cell Lines" <i>Scand. J. Immunol.</i> 26:663-672;
B16	van der Pol, W.-Ludo and van de Winkel, J.G.J. (1998) "IgG Receptor Polymorphisms: Risk Factors for Disease" <i>Immunogenetics</i> 48:222-232;

Examiner	Date Considered
----------	-----------------

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO MXI-101CPACN	SERIAL NO. 10/627307
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT van de Winkel, J.G.J.	
		FILING DATE July 25, 2003	GROUP 3763

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

Examiner

Date Considered

***EXAMINER**

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO MXI-101CPACN	SERIAL NO. 10/627307
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT van de Winkel, J.G.J.	
				FILING DATE July 25, 2003	GROUP 3763

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	D1	4,671,958	06/87	Rodwell et al.	424	1.53	
	D2	4,869,903	09/89	Lifson et al.	424	195.15	
	D3	5,026,557	06/91	Estis et al.	424	450	
	D4	5,489,525	02/96	Pastan	435	7.23	
	D5	5,578,706	11/96	Ghetie et al.	530	391.7	
	D6	5,580,715	12/96	McGrath et al.	435	5	
	D7	5,658,568	08/97	Bagshawe et al.	424	134.1	
	D8	5,686,072	11/97	Uhr et al.	424	183.1	
	D9	5,840,840	11/98	Rybak et al.	530	350	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

	D10	Bjerke et al. "Fc gamma-receptors in skin and serum from patients with psoriasis, before and after therapy." <i>Acta Derm Venereol Suppl</i> (Stockh). 1994;186:141-2
	D11	Curnow "Clinical experience with CD64-directed immunotherapy. An overview." <i>Cancer Immunol Immunother</i> . 1997 Nov-Dec;45(3-4):210-5
	D12	Ericson et al. "Monoclonal antibody 197 (anti-Fc gamma RI) infusion in a patient with immune thrombocytopenia purpura (ITP) results in down-modulation of Fc gamma RI on circulating monocytes." <i>Br J Haematol</i> . 1996 Mar;92(3):718-24

Examiner	Date Considered
EXAMINER:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.